- Frederic Vanderhaegen is leaving the company
- Search for a successor has been initiated
Männedorf, Switzerland, May 8, 2012 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that Frederic Vanderhaegen, Head of Division Life Sciences Business and member of the Group Management Board, decided to leave the company to pursue other career opportunities at Beckman Coulter Life Sciences, part of Danaher Corporation. He will leave Tecan by no later than the end of November 2012. The search for a successor is initiated.
Tecan's Board of Directors and CEO regret Mr Vanderhaegen's decision. They would like to thank him warmly for his valuable contribution to the development of Tecan and wish him all the best for the future.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Copyright Thomson Reuters
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: %s via Thomson Reuters ONE